Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Consolidated Net Income: 2018-2024

Historic Consolidated Net Income for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$257.6 million.

  • Allogene Therapeutics' Consolidated Net Income rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
  • Allogene Therapeutics' Consolidated Net Income amounted to -$257.6 million in FY2024, which was up 21.29% from -$327.3 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Consolidated Net Income ranged from a high of -$250.2 million in FY2020 and a low of -$331.0 million during FY2022.
  • For the 3-year period, Allogene Therapeutics' Consolidated Net Income averaged around -$305.3 million, with its median value being -$327.3 million (2023).
  • Per our database at Business Quant, Allogene Therapeutics' Consolidated Net Income plummeted by 35.55% in 2020 and then increased by 21.29% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Consolidated Net Income (Yearly) stood at -$250.2 million in 2020, then fell by 2.71% to -$257.0 million in 2021, then declined by 28.78% to -$331.0 million in 2022, then rose by 1.12% to -$327.3 million in 2023, then grew by 21.29% to -$257.6 million in 2024.